Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tipifarnib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tipifarnib overview
Tipifarnib (Zarnestra) is under development for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL), clear cell renal cell carcinoma, recurrent head and neck cancer squamous cell carcinoma. The drug candidate is administered orally. It is a nonpeptidomimetic quinolinone. Tipifarnib is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development.
It was also under development for the treatment of solid tumor, relapsed or refractory multiple myeloma, acute myeloid leukemia, advanced pancreatic cancer, higher risk myelodysplastic syndrome, breast cancer, glioblastoma multiforme, relapsed /refractory lymphomas including diffuse large b-cell lymphoma, mantle cell lymphoma, sezary syndrome , Hodgkin lymphoma, mycosis fungoides, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma),nodal marginal zone B-cell lymphoma, splenic marginal zone b-cell lymphoma,refractory anemia with excess blasts in transformation and anaplastic large cell lymphoma, recurrent head and neck cancer squamous cell carcinoma including oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) and Hepatitis Delta virus (HDV) infections, non-small cell lung cancer, salivary gland cancer, angioimmunoblastic T-cell lymphoma, thyroid/solid tumors with HRAS mutations, follicular T-cell lymphoma (FTCL), extranodal natural killer T-cell lymphoma, lower risk myelodysplastic syndrome, undifferentiated myeloproliferative disorders, chronic myelocytic leukemia, chronic myelomonocytic leukemia (CMML) and HRAS mutant urothelial cancer.
Kura Oncology overview
Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor to treat acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.
For a complete picture of Tipifarnib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
